Literature DB >> 22275754

The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice.

Yingben Xue1, Yongjun Xiao, Jingning Liu, Andrew C Karaplis, Martin R Pollak, Edward M Brown, Dengshun Miao, David Goltzman.   

Abstract

Although the calcium-sensing receptor (CaSR) and parathyroid hormone (PTH) may each exert skeletal effects, it is uncertain how CaSR and PTH interact at the level of bone in primary hyperparathyroidism (PHPT). Therefore, we simulated PHPT with 2 wk of continuous PTH infusion in adult mice with deletion of the PTH gene (Pth(-/-) mice) and with deletion of both PTH and CaSR genes (Pth(-/-)-Casr (-/-) mice) and compared skeletal phenotypes. PTH infusion in Pth(-/-) mice increased cortical bone turnover, augmented cortical porosity, and reduced cortical bone volume, femoral bone mineral density (BMD), and bone mineral content (BMC); these effects were markedly attenuated in PTH-infused Pth(-/-)-Casr(-/-) mice. In the absence of CaSR, the PTH-stimulated expression of receptor activator of nuclear factor-κB ligand and tartrate-resistant acid phosphatase and PTH-stimulated osteoclastogenesis was also reduced. In trabecular bone, PTH-induced increases in bone turnover, trabecular bone volume, and trabecular number were lower in Pth(-/-)-Casr(-/-) mice than in Pth(-/-) mice. PTH-stimulated genetic markers of osteoblast activity were also lower. These results are consistent with a role for CaSR in modulating both PTH-induced bone resorption and PTH-induced bone formation in discrete skeletal compartments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275754      PMCID: PMC3330707          DOI: 10.1152/ajpendo.00599.2011

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  54 in total

1.  The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure.

Authors:  M Parisien; S J Silverberg; E Shane; L de la Cruz; R Lindsay; J P Bilezikian; D W Dempster
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

2.  Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background.

Authors:  Qisheng Tu; Min Pi; Gerard Karsenty; Leigh Simpson; Shiguang Liu; L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.

Authors:  Alexander G Robling; Rajendra Kedlaya; Shana N Ellis; Paul J Childress; Joseph P Bidwell; Teresita Bellido; Charles H Turner
Journal:  Endocrinology       Date:  2011-06-07       Impact factor: 4.736

4.  Parathyroid hormone is essential for normal fetal bone formation.

Authors:  Dengshun Miao; Bin He; Andrew C Karaplis; David Goltzman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

5.  Increased renal responses to exogenous parathyroid hormone in postsurgical hypoparathyroidism.

Authors:  W M Law; H Heath
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

6.  Bone is a target for the antidiabetic compound rosiglitazone.

Authors:  S O Rzonca; L J Suva; D Gaddy; D C Montague; B Lecka-Czernik
Journal:  Endocrinology       Date:  2003-09-18       Impact factor: 4.736

7.  Continuous parathyroid hormone induces cortical porosity in the rat: effects on bone turnover and mechanical properties.

Authors:  Sutada Lotinun; Glenda L Evans; James T Bronk; Mark E Bolander; Thomas J Wronski; Erik L Ritman; Russell T Turner
Journal:  J Bone Miner Res       Date:  2004-04-12       Impact factor: 6.741

8.  Bone mineral density and skeletal fractures in familial benign hypercalcemia (hypocalciuric hypercalcemia).

Authors:  W M Law; H W Wahner; H Heath
Journal:  Mayo Clin Proc       Date:  1984-12       Impact factor: 7.616

9.  Skeletal disease in primary hyperparathyroidism.

Authors:  S J Silverberg; E Shane; L de la Cruz; D W Dempster; F Feldman; D Seldin; T P Jacobs; E S Siris; M Cafferty; M V Parisien
Journal:  J Bone Miner Res       Date:  1989-06       Impact factor: 6.741

Review 10.  Parathyroid hormone: a double-edged sword for bone metabolism.

Authors:  Ling Qin; Liza J Raggatt; Nicola C Partridge
Journal:  Trends Endocrinol Metab       Date:  2004-03       Impact factor: 12.015

View more
  15 in total

Review 1.  Signaling pathways affecting skeletal health.

Authors:  Pierre J Marie
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

2.  Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.

Authors:  Sharon M Moe; Leah Wetherill; Brian Scott Decker; Dongbing Lai; Safa Abdalla; Jin Long; Matteo Vatta; Tatiana M Foroud; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-19       Impact factor: 8.237

Review 3.  The calcium-sensing receptor in bone--mechanistic and therapeutic insights.

Authors:  David Goltzman; Geoffrey N Hendy
Journal:  Nat Rev Endocrinol       Date:  2015-03-10       Impact factor: 43.330

Review 4.  The calcium-sensing receptor in bone metabolism: from bench to bedside and back.

Authors:  L Cianferotti; A R Gomes; S Fabbri; A Tanini; M L Brandi
Journal:  Osteoporos Int       Date:  2015-06-23       Impact factor: 4.507

5.  Calcium Sensing Receptor Function Supports Osteoblast Survival and Acts as a Co-Factor in PTH Anabolic Actions in Bone.

Authors:  Saja A Al-Dujaili; Amy J Koh; Ming Dang; Xue Mi; Wenhan Chang; Peter X Ma; Laurie K McCauley
Journal:  J Cell Biochem       Date:  2016-02-19       Impact factor: 4.429

6.  Quantitative trait loci for bone mineral density and femoral morphology in an advanced intercross population of mice.

Authors:  Larry J Leamy; Scott A Kelly; Kunjie Hua; Charles R Farber; Daniel Pomp
Journal:  Bone       Date:  2013-02-26       Impact factor: 4.398

7.  A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.

Authors:  Johan Halse; Susan Greenspan; Felicia Cosman; Graham Ellis; Arthur Santora; Albert Leung; Norman Heyden; Suvajit Samanta; Steven Doleckyj; Elizabeth Rosenberg; Andrew E Denker
Journal:  J Clin Endocrinol Metab       Date:  2014-08-28       Impact factor: 5.958

Review 8.  The osteocyte as a therapeutic target in the treatment of osteoporosis.

Authors:  Gaël Y Rochefort
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

9.  FAM210A is a novel determinant of bone and muscle structure and strength.

Authors:  Ken-Ichiro Tanaka; Yingben Xue; Loan Nguyen-Yamamoto; John A Morris; Ippei Kanazawa; Toshitsugu Sugimoto; Simon S Wing; J Brent Richards; David Goltzman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-04       Impact factor: 11.205

10.  Skeletal toxicity resulting from exposure of growing male rats to coplanar PCB 126 is associated with disruption of calcium homeostasis and the GH-IGF-1 axis and direct effects on bone formation.

Authors:  Martin J Ronis; James Watt; Casey F Pulliam; Ashlee E Williams; Alexander W Alund; Ezazul Haque; Gopi S Gadupudi; Larry W Robertson
Journal:  Arch Toxicol       Date:  2019-12-09       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.